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Nuclear medicine imaging techniques oﬀer whole body imaging for localization of number and site of infective foci inspite of
limitation of spatial resolution. The innate human immune system contains a large member of important elements including
antimicrobial peptides to combat any form of infection. However, development of antibiotics against bacteria progressed rapidly
and gained popularity over antimicrobial peptides but even powerful antimicrobials failed to reduce morbidity and mortality
due to emergence of mutant strains of bacteria resulting in antimicrobial resistance. Diﬀerentiation between infection and
inﬂammation using radiolabeled compounds with nuclear medicine techniques has always been a dilemma which is still to be
resolved. Starting from nonspeciﬁc tracers to speciﬁc radiolabeled tracers, the question is still unanswered. Speciﬁc radiolabeled
tracers included antibiotics and antimicrobial peptides which bind directly to the bacteria for eﬃcient localization with advanced
nuclear medicine equipments. However, there are merits and demerits attributed to each. In the current paper, radiolabeled
antibiotics and radiolabeled peptides for infection localization have been discussed starting with the background of primitive
nonspeciﬁc tracers. Radiolabeled antimicrobial peptides have certain merits compared with labeled antibiotics which make them
superior agents for localization of infective focus.
1. GeneralIntroduction
Blood-derived antimicrobial proteins and peptides being
part of innate immunity target the microbial membranes
leading to growth arrest and, in some instants, neutralization
ofproinﬂammatorysurfacecomponentslikelipopolysaccha-
rides. Diﬀerent inﬂammatory response blood cells like neu-
trophils, eosinophils, macrophages, and platelets contain an-
timicrobial proteins and peptides which have aﬃnity for sur-
face lipids of microbial as opposed to eukaryotic cells. Neu-
trophils contain primary and secondary granules in their cy-
toplasm which contain antimicrobial proteins and peptides.
Lactoferrin is localized in the secondary granules, which has
direct microbicidal eﬀect, presumably via membrane disrup-
tion. Activated neutrophils release bactericidal/permeability
increasing protein (BPI) into inﬂammatory ﬂuids where it is
potentiallybactericidal.Serprocidinsareproteaseswithcyto-
toxic activity localized in neutrophil primary granules.
Cathelicidins are also antimicrobial peptides within second-
ary granules of neutrophils. The defensins are a family of 4-
Kdpeptideswithbroadcytotoxicactivityagainstbacteria,fu-
ngi, parasites, viruses, and host cells. Humans express α-de-
fensins in neutrophils and β-defensins in intestinal Paneth
cell,aswellaspulmonaryandreproductiveepithelia.Thede-
fensins peptides, calprotectin protein, and ubiquicidin ca-
tionic peptides are found in macrophages [1]. Platelet α-
grounds contain certain cationic antimicrobial peptides hav-
ing broad spectrum antimicrobial activity [2]. Multiple pro-
teins and peptides have been radiolabelled by multiple inves-
tigatorsforspeciﬁclocalization ofinfection focibuteachhad
certain demerits. More attention diverted to development of
new antibiotics followed by radiolabeling but these face the
growing problem of microbial resistance.
Diﬀerentiation between infection and inﬂammation is
usuallydiﬃcult.Cliniciansuseavarietyofclues,forexample,
clinical, laboratory, and radiological tests, to aid in diagnosis2 International Journal of Peptides
and inﬂuence decision making. Commonly employed and
useful modalities for demonstration of any focal lesion in-
clude conventional radiological techniques such as X-ray, ul-
trasound, computerized tomography (CT), magnetic reso-
nance imaging (MRI), which demonstrate structural abnor-
malities which take some time to become visible, may not
always be present, and their resolution lag behind cure. In
addition they are neither inﬂammation nor infection speci-
ﬁc. Nuclear medicine has enhanced infection imaging be-
cause it depends on the demonstration of pathophysiological
and pathological changes, which occur earlier in infection
process and also resolve quicker after cure of the infection
compared with gross changes in structure [3]. Scintigraphic
imaging of inﬂammation can be achieved in two ways. The
ﬁrstistoutilizethelocallyenhancedvascularpermeabilityby
injecting radiolabelled molecules that show increased extra-
vasation at the site of infection/inﬂammation. The alterna-
tive is to exploit the diapedesis and chemotaxis of leucocytes,
either by radiolabelling white blood cells of the patients
exvivoorbydirectlytargetingleukocyteantigensorreceptors
in vivo via administration of radiolabelled antigranulocyte
monoclonal antibodies on receptor-binding ligands [4].
However, nuclear medicine utilizes radiation and must be
used as a diagnostic modality in cases where other noniso-
topic and noninvasive techniques fail to achieve the target.
Scintigraphy has the advantage of early elucidation of
pathophysiological changes in the infective process; however,
it is limited by poor resolution. Recent advances in nuclear
medicine technology resulted in commercially available
instrumentation such as single-photon emission computed
tomography (SPECT) and positron emission tomography
(PET) that have markedly improved anatomical details.
Autologous invitro 111In-oxinate-or 99mTc-HMPAO-labeled
leukocytes are still the gold standard for imaging infections
[5–7]. Planar images with gamma cameras are handicapped
with limited resolution that is not suﬃcient for assessing
the extent of disease. SPECT increases the sensitivity of the
nuclear medicine procedures [8, 9], but precise anatomical
localization of organs is still not possible. Hybrid SPECT/CT
improves the diagnostic accuracy when subjected to 99mTc-
HMPAO-labeledleukocytesinpatientswithsuspectedosteo-
myelitis [10]. Marked improvement in sensitivity and def-
inition of the extent of infection has been documented with
SPECT/CT using 67Ga- and 111In-labeled leukocytes [11].
PET/CT with 18F-FDG-labeled autologous leukocytes has
further improved the diagnosis and localization of infection
lesions [12]; however, the technique is time consuming, de-
mandsasterileenvironment,andcarriestheriskoftransmis-
sion of blood-borne diseases. Antimicrobial compounds that
bind to the bacteria would be speciﬁc for infection loca-
lization if labeled with a suitable isotope because of their
selective adhesion to the causative agents [3]. An early anti-
biotic radiopharmaceutical was 99mTc-ciproﬂoxacin, which
isananalogofabroad-spectrumquinoloneantibiotichaving
the property of binding to DNA gyrase of bacteria and in-
hibiting DNA synthesis [13]. This 99mTc agent showed en-
couraging results in various infections [14–16]; however,
speciﬁcity was lower than expected, and its accumulation in
noninfectious/inﬂammatory sites has also been reported
[17].Duetononspeciﬁcaccumulationininﬂammatorysites,
thisagenthasbeenproposedforidentifyingthepresenceand
distribution of inﬂammation within joints [18]. Bacterial
resistance to ciproﬂoxacin is another disadvantage, which re-
sults in false-negative results [19].
Antimicrobial peptides, produced by phagocytes, epithe-
lial cells, endothelial cells, and many other cell types, are an
important component of innate immunity against infection
by a variety of pathogens [20]. These peptides show anti-
bacterial,antiviral,andantifungalactivities invitro. Bacterial
infections with Staphylococcus aureus and Klebsiella pneumo-
niae have been visualized in mice by 99mTc-labeled human
neutrophil peptide-1 [21]. The basis of the antimicrobial
activity of these peptides is the interaction of the cation-
ic domains with the negatively charged surface of the micro-
organisms. The antimicrobial peptide ubiquicidin UBI (29–
41) (TGRAKRRMQYNRR; 1,693Da) was originally isolated
from mouse macrophage cells. This peptide is identical or
highly homologous to S30, a protein that was puriﬁed from
the small ribosomal subunit fraction of rat liver and shown
to be present in various human and murine tissues [22]. La-
ter, an identical UBI was isolated from human airway epi-
thelial cells. This peptide was labeled with 99mTc, which
targetedbacterialcellsbutnot sterileinﬂammatoryprocesses
in experimental animals [23]. In later experiments, it also
showed accumulation with high accuracy in fungal infec-
tions. This tracer was also used for detection of Staphylo-
coccus aureus infections in mice and Klebsiella pneumoniae
in rabbits. As controls, inﬂammation was produced by lipo-
polysaccharides(LPSs)andheat-killedmicroorganisms[24].
Interactions of cationic peptides with bacterial envelopes in-
volveinsertionofthepeptideintomicrobialmembranes[25]
andpossiblyasequence-dependentinteractionoftheantimi-
crobial peptides with microorganisms [26]. Multiple animal
studies using 99mTc-labeled ubiquicidin (29–41) showed
encouraging results for diﬀerentiation between infection
and inﬂammation model. 99mTc-UBI (29–41) scintigraphy
showed more accumulation of tracer in Staphylococcus-
aureus-induced infection compared with that of Escherichia
coli infection model. Optimum time for imaging was 60min
after tracer injection [27]. In another study with this radio-
labelled peptide, it was concluded that its accumulation is
directly related to viable number of bacteria as tracer accu-
mulation in infective foci declined after administration of
ciproﬂoxacin which reduced the number of bacteria sensitive
to this antibiotic. However, serial imaging with 99mTc-UBI
can be utilized for monitoring eﬃcacy and direction of an-
tibiotictreatment[28]. Use of radiolabeled antimicrobial pe-
ptides is only recommended in cases where physician or sur-
geon is in dilemma to diﬀerentiate infection from inﬂamma-
tion. This would avoid blind use of prophylactic antibiotics
or as broad spectrum coverage of infection, which results in
heavy expenditure and side eﬀects of unnecessary medicines.
Phase-I clinical trial with this novel radiolabelled peptide
showed overall sensitivity, speciﬁcity, and accuracy of 100%,
80%, and 94.4%, respectively, in patients with soft tissue in-
fections and osteomyelitis. However, optimum time for
imaging was 30min after intravenous administration of ra-
diotracer [29].International Journal of Peptides 3
2. Detection of Infection by
Nonspeciﬁc Tracers
2.1. Gallium-67-Citrate. The oldest radiopharmaceutical
proposed for imaging inﬂammation is Gallium-67 citrate
which has been used for infection and inﬂammation ever
since its discovery in 1971 [30]. 67Ga is a cyclotron-produced
radionuclide, with a half-life of 78 hours, emits a broad spec-
trum of gamma rays between 93keV and 880keV. The en-
ergy peaks that are most suitable for gamma camera imag-
ing are 93keV, 184keV, 296keV, and 388keV [31]. After
intravenous injection, 67Ga binds to transferrin. This com-
plex extravasates at the site of inﬂammation due to the lo-
cally enhanced vascular permeability, and in the inﬂamma-
tory lesion it may transchelate to lactoferrin as present in
leukocytes.TheB-lymphocyteshavelactoferrin-bindingsites
on their surface, which have high aﬃnity for gallium. Ad-
ditionally, macrophages engulf protein iron complexes and
cellular debris, thereby accumulating gallium. Bacteria and
fungi contain siderophores which are released for the pur-
pose of scavenging iron and consequently bind gallium as a
gallium-siderophore complex [32]. The agent is excreted pa-
rtly via the kidneys (especially during the ﬁrst 24 hours after
injection)andviathegastrointestinaltract;thereforecolonis
the target organ. Oral laxatives to reduce bowel activity and
to reduce dose to large bowel are not required [33, 34]. Phy-
siological uptake of the radiolabel also occurs in liver, bone,
bone marrow, salivary glands, nasopharynx, and lacrimal
glands. For infection or inﬂammation, imaging can often be
accomplished at 48 hours, or even 24 hours, after injection.
Planar imaging is performed in the anterior and posterior
projection, to include the head, neck, chest, abdomen, pelvis,
and proximal extremities. SPECT imaging is performed at 72
hours, which improves the sensitivity and speciﬁcity. Most
patients exhibit bowel activity at this time; therefore planar
and SPECT imaging of abdomen can be performed at 5–
7 days after injection. Inspite of SPECT imaging, there are
low spatial resolution and the lack of anatomic landmarks of
scintigraphy [35].
Although 67Ga-citrate scintigraphy has high sensitivity
for both acute and chronic infection and noninfectious in-
ﬂammation,thereareseveralshortcomingsthatlimititsclin-
ical application. The speciﬁcity of the technique is low, due
to physiological bowel excretion and accumulation in ma-
lignanttissuesandareasofboneremodeling.Inaddition,the
radiopharmaceutical has unfavorableimaging characteristics
(long physical half-life and high energy gamma radiations),
causing high radiation-absorbed doses. Furthermore, opti-
mal imaging often requires delayed recordings up to 72
hours. These unfavorable characteristics, in combination
with the development of newer radiopharmaceuticals, have
narrowed the clinical indication for gallium scintigraphy to
certain conditions such as lung infections and chronic os-
teomyelitis. The sensitivity and speciﬁcity for chronic osteo-
myelitisarelowerthanforacuteosteomyelitis[36,37].Useof
SPECT/CT with 67Ga improves diagnostic eﬃciency as com-
pared with planar or SPECT scanning [11]. Gallium scan
is most often used in patients with fever of known
origin (FUO), suspected vertebral osteomyelitis, chronic
osteomyelitis, pulmonary/mediastinal infections, tuberculo-
sis, sarcoidosis, and retroperitoneal ﬁbrosis. This agent is
also valuable for evaluation and followup of drug-induced
pulmonary toxic agents like bleomycin and amiodarone. Im-
munocompromised and neutropenic patients are also candi-
dates for evaluation with gallium scanning [38].
2.2. Nonspeciﬁc Immunoglobulins. Initially it was hypothe-
sized that human polyclonal immunoglobulin (HIG) was
retained in infectious foci owing to the interaction with Fc-Υ
receptors as expressed on inﬁltrating leucocytes [39]. Later
studies showed that radiolabelled HIG accumulates in
infectious foci by nonspeciﬁc extravasation due the locally
enhanced vascular permeability [40]. For clinical use, HIG
has been labeled with 111In-oxinate as well as with 99mTc.
Both agents have slow blood clearance and physiological up-
takeintheliver,thespleen,andthekidneys.The 99mTc-label-
ed preparation has the known ideal radiation characteristics,
while the 111In-labeled preparation allows imaging at time
points beyond 24 hours after injection. 111In-oxinate or
99mTc-labeled HIG has been extensively tested in a large
number of clinical studies. It has shown excellent perfor-
mance in the localization of musculoskeletal infection and
inﬂammation [41]. In addition, good results have been re-
ported in pulmonary infection particularly in immunocom-
promised patients [42] and abdominal inﬂammation. A ge-
neral limitation is the long time span between injection and
ﬁnal diagnosis (24–48 hours) [43, 44].
2.3. Liposomes. Liposomes are spheres consisting of one or
morelipidbilayerssurroundinganaqueousspace.Theywere
proposed as vehicles to image infection some 20 years ago,
but the preparations used in those early years were cleared
from the circulation very rapidly by the mononuclear phago-
cyte system (MPS). However, if the surface of the liposomes
is coated with a hydrophilic polymer such as polyethylene
glycol (PEG), they circumvent recognition by the MPS,
leading to a prolonged residence time in the circulation
and enhanced uptake at pathological sites by extravasation
due to locally enhanced vascular permeability [45]. Such
stabilized PEG-liposomes can be labeled with 111In-oxinate
and with 99mTc, either using hexamethylpropylene amine
oxime (HMPAO) as an internal label or via HYNIC as an
external chelator. Labeling is easy and takes only minutes
[46]. The ﬁrst clinical evaluation showed good imaging of
focal infection. In patients suspected of harboring infectious
orinﬂammatorydisease, 99mTc-PEG-liposomesweredirectly
compared with 111In-IgG scintigraphy. 99mTc-PEG-liposome
scintigraphyhasshownhighsensitivity(94%)andspeciﬁcity
(89%) [47].
2.4. The Avidin-Biotin System. Avidins are a family of pro-
teins present in the eggs of amphibians, reptiles, and birds;
streptavidin is a member of the same family. Avidin and
streptavidin (mol. wt. 66,000 and 60,000, resp.) bind to bio-
tin with extremely high aﬃnity. Biotin is a compound
of low molecular weight that can be radiolabelled. The
avidin-biotin approach is based on the fact that avidin (or
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owing to increased vascular permeability. Avidin (or strep-
tavidin) is injected as a pretargeting agent, followed hours
later by a second injection with radiolabelled biotin. Good
diagnostic accuracy was demonstrated in studies of vascular
infection and chronic osteomyelitis [48–51].
3.Detectionof InfectionbySpeciﬁc Tracers
3.1. Radiolabeled White Blood Cells. Ex vivo labeled autol-
ogous leucocytes were developed in the 1970s and 1980s
and their use is still considered the “gold standard” nuclear
medicine technique for infection and inﬂammation imaging
[5–7]. Although a variety of in vitro leukocyte-labeling tech-
niques have been used, the most commonly used procedure
makes use of the lipophilic compounds 111In-Oxyquinoline
and 99mTc-HMPAO. The radiolabeling procedure takes
about 2-3 hours. Because all the cellular components of the
bloodcanbelabeled,itisnecessarytoseparatetheleukocytes
from the erythrocytes and platelets. After withdrawal, there-
fore, the syringe containing the blood is kept in the upright
positionforabout1-2hourtopromoteerythrocytesedimen-
tation. After the erythrocytes have been separated, the leuko-
cytes must be separated from platelets. The leukocyte-rich
plasma is centrifuged, and the leukocyte pellet that forms
at the bottom of the tube is removed, incubated with the ra-
diolabel, washed, and reinjected into the patient. The us-
ual dose of 111In-labeled leukocytes is 10–18.5MBq (300–
500μCi); the usual dose of 99mTc-HMPAO-labeled leuko-
cytes is 185–370MBq (5–10mCi). Uptake of labeled leuko-
cytes is dependent on intact chemotoxis, the number and
types of cells labeled, and the cellular component of a par-
ticular inﬂammatory response. A total white cell count of at
least 2000/mm3 is needed to obtain satisfactory images. Neu-
trophils can be radiolabeled and hence the procedure is most
useful for identifying neutrophil-mediated inﬂammatory
processes, such as bacterial infections. The procedure is less
useful for those illnesses in which the predominant cellular
responseisotherthanneutrophilic,suchastuberculosis[52].
3.1.1. 111In-Oxine-Labeled Leukocytes. F o ro v e rt w od e c a d e s ,
111In-oxine-labeled leukocytes have been used to image
infection and inﬂammation. The scintigraphic images reﬂect
the distribution of white blood cells in the body. Since an
abscess or other localized infection consists primarily of
leukocytes, the radiopharmaceutical localizes at the site of
infection [53–61]. After intravenous administration, there is
initial sequestration of the labeled leucocytes in the lungs,
with subsequent rapid clearance of the activity from the
lungs. The radiolabel rapidly clears from the blood and in
most cases there is high uptake in granulocytic inﬁltrates,
while a substantial portion of the leucocytes (presumably the
damaged cells) accumulate in the spleen. Thus, as a radio-
pharmaceutical, radiolabelled leucocytes are a speciﬁc indi-
catorforleukocyticinﬁltration,butnotforinfection[62,63].
At 24 hour, after injection, the usual imaging time for 111In-
labeled leukocytes, the normal distribution of activity is
limited to the liver, spleen, and bone marrow. Large ﬁeld of
view gamma camera equipped with medium energy parallel
Table 1: Causes of false-negative and false-positive 111In leukocyte
studies.
False Negative
Encapsulated nonpyogenic abscess
Vertebral osteomyelitis
Chronic low-grade infection
Parasitic, mycobacterial or fungal infections
Intrahepatic, perihepatic, or splenic infection
Hyperglycemia
Steroids
False Positive
Gastrointestinal bleeding
Pseudoaneurysm
Healing fracture
Soft tissue tumor
Surgical wounds, stomas, or catheter sites
Tumors
Accessory spleens
hole collimator is used with 15% window centered on 174-
Kev photopeak and 20% window centered on the 247-Kev
photopeak. Advantages of the 111In label are a very stable
label and constant normal distribution of activity limited to
liver, spleen, and bone marrow. The 67-hour half-life of
isotopeallowsdelayedimaging,whichisparticularlyvaluable
in musculoskeletal infection. Another advantage is conduc-
tion of bone or bone marrow scan immediately after com-
pletion of 111In-labeled study which is a limitation with
99mTc-labeled tracers [9]. Disadvantages of the 111In label in-
clude a low photon ﬂux, less than ideal photon energies, and
the fact that a 24-hour interval between injection and ima-
ging is generally required. Causes of false-negative and false-
positive 111In-leukocyte study are summarized in Table 1
[64]. Drawbacks of 111In-labeled white blood cells are labori-
ous and time-consuming preparation, requiring specialized
equipment and can be hazardous. Almost 3 hours are re-
quired for isolating and labeling a patient’s white blood cells
by a trained technician. In addition, the need to handle po-
tentially contaminated blood can lead to transmission of
blood-bornepathogenssuchasHIVandHBV.Asanatomical
land marks are not properly outlined with scintigraphy, the
same is the limitation with 111In-WBC planar images. How-
ever, SPECT/CT with 111In-WBC scintigraphy markedly
improves accurate identiﬁcation of infection sites [11].
3.1.2. 99mTc-HMPAO-Labeled Leukocytes. The normal bio-
distribution of 99mTc-HMPAO-labeled leukocytes is more
variable. In addition to the reticuloendothelial system, ac-
tivityisalsonormallypresentinthegenitourinarytract,large
bowel, blood pool, and occasionally the gall bladder [65].
The interval between injection and imaging varies with indi-
cation; in general, imaging is usually performed within a few
hours after injection. 99mTc-HMPAO has theoretical advan-
tages over 111In-labeled leukocytes. 99mTc, being generator
produced on site, could be immediately available for radi-
olabeling. The radiation dose to the patient would beInternational Journal of Peptides 5
signiﬁcantlylower,permittingahigheradministeredactivity.
The higher photon yield of 99mTc would result in superior
image resolution and improved infection detectability and
accuracy.
HMPAO preferentially labels granulocytes, a potential
advantage for imaging acute purulent processes. Unlike
111In-oxine-labeled leukocytes, 99mTc-HMPAO-labeled leu-
kocytes are cleared by the hepatobiliary and renal systems
[65–70]. Disadvantages include genitourinary tract activity,
which appears shortly after injection and colonic activity
which appears 4 hours after injection. The instability of the
label and the short half-life of 99mTc are disadvantages when
24-hour imaging is needed. This occurs in those infections
that tend to be indolent and for which several hours may be
necessary for accumulation of a suﬃcient quantity of labeled
leukocytes to be successfully imaged. Bone or bone marrow
scan if indicated after 99mTc-HMPAO-WBC scan has to be
delayedatleastfor48hoursandpreferably72hours.Forbet-
ter anatomical localization of infection site, SPECT/CT with
99mTc-HMPAO-WBC scintigraphy is far better than pla-
nar/SPECT imaging with other infecting imaging agents
[10].
3.2. Antigranulocyte Antibodies and Antibody Fragment. Sev-
eral monoclonal antibodies reactive with antigens expressed
on granulocytes (NCA, CD15, CD66, and CD67) have
been developed. At least three antigranulocyte antibodies
have been tested for infection imaging: anti-NCA-95 IgG
(BW250/183)[71,72],anti-NCA-90Fab’(Immu-MN3,Leu-
koScan: anti-CD66) [73], and anti-SSEA-1 IgM (LeuTech:
anti-CD15) [74–76]. Each of these antigranulocyte antibod-
ies labeled with 99mTc or 123I allowed accurate delineation
of infection [59]. The antigranulocyte antibody-based radio-
pharmaceuticals visualized infectious foci in patients with
sensitivity between 80% and 90% [77].
The use of antibody fragments instead of the whole anti-
body seems to be more advantageous, since such fragments
appear to be less immunogenic. In addition, antibody frag-
ments show faster blood clearance and may thus provide ear-
lier diagnosis. 99mTc-labeled antigranulocyte Fab’ fragment
(LeukoScan) has been registered in Europe as an infection
imaging agent.
3.3. Chemotactic Peptides. A wide variety of peptides that
bind to receptors expressed on white blood cells have been
tested for the detection of infection. One of the ﬁrst receptor
binding peptide tested for its ability to image infectious foci
was chemotactic peptide formyl-Met-Leu-Phe. This tripep-
tide, which is N-terminally formylated, is a chemotactic fac-
tor produced by bacteria which binds to receptors on gran-
ulocytes and monocytes with high aﬃnity [78–80]. A draw-
back of using these biologically potent peptides is a transient
but severe reduction in peripheral leukocyte counts. Several
antagonists were developed to circumvent this undesirable
biological activity of the radiolabelled chemotactic peptide.
However, these antagonists had lower uptake in the infec-
tious focus, most likely owing to reduced aﬃnity for the re-
ceptor [81].
3.4. Cytokines. The attraction of leukocytes to tissues is es-
sential for inﬂammation and host response to infection. The
process is controlled by chemokines, which are chemotactic
cytokines. Over 40 chemokines have been identiﬁed to date,
most of them in the past few years. Chemokines induce cell
migration and activation by binding to speciﬁc G-protein-
coupled cell surface receptors on target cells. Their receptors
are expressed on diﬀerent types of leukocytes. Some are re-
stricted to certain cells, whereas others are more widely
expressed [82]. Labeled cytokines are an interesting class
of protein radiopharmaceuticals of low molecular weight
(<20,000).
3.5. Interleukin-1. Interleukin-1 (IL-1) binds receptors ex-
pressed mainly on granulocytes, monocytes, and lympho-
cytes, with high aﬃnity. Studies in mice with focal Staphylo-
coccus aureus infections showed speciﬁc uptake of radioiodi-
nated IL-1 at the site of infection [83]. Fever, haemodynamic
and hematological side eﬀects, occurring even at very low
concentrations, are the major drawbacks of the use of such
a biologically active protein [84].
3.6. Interleukin-2. The IL-2 is considered to bind speciﬁcally
to IL-2 receptors expressed on activated T lymphocytes. In a
study in an animal model of human autoimmune diabetes
mellitus, Hashimoto’s thyroiditis, Grave’s disease, Crohn’s
disease, Coeliac disease and other autoimmune diseases, de-
monstrated localization of 123Io r99mTc-labeled IL-2 at the
site of lymphocytic inﬁltration [85, 86].
3.7. Interleukin-8. IL-8 binds to receptors on neutrophils
with high aﬃnity. In rabbits with focal Escherichia coli infec-
tion, accumulation of 123I-labeled IL-8 in the abscess was
rapid and high. The speciﬁc activity of this IL-8 prepara-
tion was relatively low, resulting in a transient reduction
in peripheral leukocyte counts to 45% after a dose of
25μg/kg 123I-IL-8,followedbyleukocytosisforseveralhours.
Recently, a 99mTc-labelled IL-8 preparation was developed
using HYNIC as a chelator. In rabbits with Escherichia coli
infection, high abscess uptake of 99mTc-HYNIC-IL-8 and
high abscess-to-background ratios were obtained compared
with those obtained using the radioiodinated preparation
[87–91].
3.8. Platelet Factor-4. Platelet factor 4 (PF-4), like IL-8, is a
member of the CXC chemokines. PF-4 binds the CXC type II
(= IL-8 type B) receptors expressed on neutrophils and mo-
nocytes. In a rabbit model of infection, 99mTc-P483H clearly
delineated the infectious foci as early as 4 hours after in-
jection.Nosystemicsideeﬀectswereobserved. 99mTc-P483H
has been studied in patients to test its applicability as an
imaging agent for scintigraphic detection of infection and
inﬂammation, with fair results (82% sensitivity, 77% speci-
ﬁcity) [92, 93].
3.9. Detection of Infection by 18F-Deoxyglucose (FDG). FDG
is transported into cells by glucose transporters and is phos-
phorylatedbyhexokinaseenzymeto 18F-2-FDG-6phosphate6 International Journal of Peptides
but is not metabolized. The degree of cellular FDG uptake is
related to the cellular metabolic rate and the number of glu-
cose transporters [94–96]. Activated inﬂammatory cells also
demonstrate increased expression of glucose transporters. In
addition, in inﬂammatory conditions, the aﬃnity of gluc-
ose transporters for deoxyglucose is apparently increased by
various cytokines and growth factors, a phenomenon that
has not been observed in tumors [97]. Although FDG up-
takecanproducefalse-positiveresultsinpatientswithknown
orsuspectedmalignancy,FDGrepresentsanotherpotentially
useful radiotracer in the setting of infection and inﬂamma-
tion. The areas of normal distribution of FDG include the
brain, myocardium, and genitourinary tract. Activity in the
bone marrow, stomach, and bowel is variable [98]. Thymic
uptake, especially in children, can also be observed [99].
Hepatic and splenic uptake are generally of low grade and
diﬀuse; however intense uptake in spleen may be visualized
in the setting of infection [100].
Positron emission tomography (PET) with 18FDG is now
widely used. FDG is taken up by inﬂammatory cells with in-
creased metabolic requirements. In contrast to glucose, de-
oxyglucose cannot leave the cell once it is taken up, so it can
be used to image scintigraphically cells with high glucose up-
take such as tumor cells and inﬂammatory cells. FDG-PET
has been studied in a wide variety of infections, including
lesions of bacterial, tuberculous, fungal, soft tissue, and bone
infections [101, 102]. Sensitivity and speciﬁcity have gener-
ally exceeded 90%. This radiotracer has high positive pre-
dictive value to localize in infective sites of patients with
AIDS and fever of unknown origin (FUO). This technique
accurately helps identify sites of infective endocarditis and
is promising supplement to conventional echocardiography
[103]. FDG-PET has been especially successful in cases of
osteomyelitis [104–107]. For vertebral osteomyelitis, high
sensitivity, speciﬁcity, and accuracy comparable to those of
gallium imaging have been reported [108]. High spatial re-
solution and rapid accumulation in infectious foci are sig-
niﬁcant advantages over conventional imaging techniques
such as the use of labeled leucocytes. However, the fact that
uptake occurs in any cell type with high glycolytic activity
is a serious limitation of the use of FDG-PET for infection
imaging, restricting its speciﬁcity [109]. PET is highly sen-
sitive but may be unable to deﬁne the anatomic location
of a focus of increased 18F-FDG accumulation. The hybrid
PET/CT technology improved diagnostic accuracy with
preciseregistrationofmetabolicandstructuralimagingdata.
18F-FDG PET/CT utilized for workup of osteomyelitis in
diabetic foot correctly identiﬁed 93% of all infected sites
[110]. However, 18F-FDG-WBC is a nonspeciﬁc tracer of in-
creased glucose metabolism and does not accumulate only
in sites of infection and inﬂammation but also shows false-
positive results in tumor and postoperative changes [111].
18F-FDG-labeled autologous leukocytes PET/CT for infec-
tion detection has demonstrated sensitivity, speciﬁcity, and
accuracy of 91%, 85%, and 90%, respectively. Negative
predictive value of 100% with this technique is a hallmark.
18F-FDG-WBC imaging is superior to 18F-FDG alone for in-
fection detection as well as for assessment of response of
infectiontoantibiotictreatment;howeverlimitedavailability
and cost are the limitations [12].
3.10. Detection of Infection by Radiolabeled Antibiotics
3.10.1. Ciproﬂoxacin. The ﬁrst antibiotic developed as a ra-
diopharmaceutical was 99mTc-ciproﬂoxacin having many of
the properties of an ideal infection-speciﬁc agent [3]. Cipro-
ﬂoxacin is a broad spectrum quinolone which binds specif-
ically to bacterial DNA gyrase, inhibits DNA synthesis, and
has been proposed to distinguish infection from inﬂamma-
tion [112, 113]. It is retained at sites of infection and as-
sociates freely with metal ions, allowing it to be labeled with
technetium.Ciproﬂoxacinalsobindstotheequivalentmam-
malianenzyme,topoisomerase II,butwith100to1000times
lesser aﬃnity and the binding is readily reversible. Similarly,
it penetrates neutrophils, macrophages, and other cells and
tissues, but is not retained for prolonged periods. Thus after
the initial distribution phase, as the serum concentration
falls, the antibiotic readily leaches out of the cells and tissues
into tissue ﬂuid and then the blood and excreted freely,
predominantly in the urine. However, it is retained at sites of
infection, giving high target to background ratio permitting
infection-speciﬁc imaging when sequential images are taken
at 1, 4 and if required 24 hours after injection [3].
In vitro, ciproﬂoxacin is taken up by a wide variety of
Gram-positive, Gram-negative, and anaerobic bacteria (in-
cluding ciproﬂoxacin-resistant bacteria as long as the resis-
tance is not mediated by cell membrane impermeability,
which prevents entry of the antibiotic into the bacterial cell)
but not by dead bacteria or white cells [114, 115]. Biodis-
tribution and dosimetry of 99mTc-ciproﬂoxacin show rapid,
predominantly urinary excretion of the tracer, with low-to-
absent brain, lung, and bone marrow uptake and low liver
uptake and excretion. Highest radiation dose was received
by urinary bladder. Imaging conditions were excellent for
both thoracic and abdominal regions, even at early time (60
minutes) after injection [116]. In a comparative study in
51 patients, it demonstrated greater speciﬁcity (96%) for
imaging infection compared with white cell imaging (84%)
[113]. High speciﬁcity for bacterial infection was conﬁrmed
in a subsequent study involving 90 patients [117]. It also
showed that some infections due to ciproﬂoxacin-resistant
bacteria could be imaged and that prior antibiotic treatment
did not signiﬁcantly aﬀect the imaging result. The sensitivity
and speciﬁcity of ciproﬂoxacin imaging have been validated
further in a large multicentre study involving 879 patients,
with a wide variety of infective and noninfective conditions
(including noninfective inﬂammatory disorders), in eight
countries, under the auspices of the International Atomic
Energy Agency (IAEA) [118]. No adverse reactions occurred
and antibiotic-resistant organisms did not emerge as a re-
sultoftheadministrationofantibioticintopatients.Thiswas
expected because only a tracer dose of ciproﬂoxacin is
present in the kit, 2mg, which is 1/200th of a single thera-
peutic intravenous dose of ciproﬂoxacin (400mg). Sensi-
tivity (85.4%) and speciﬁcity (81.7%) for imaging sites of
infection were good, but varied according to the type ofInternational Journal of Peptides 7
infections imaged. The highest sensitivity (in excess of 90%)
was seen in osteomyelitis, septic arthritis, infection of ortho-
pedic prostheses (which is often diﬃcult to diagnose by stan-
dard techniques and diﬀerentiate from aseptic loosening),
and culture-proven soft tissue and abdominal infections and
tuberculosis. Ciproﬂoxacin has several advantages over esta-
blished, for example, radiolabeled leucocytes, and other
methods for imaging infection, which include the following:
(1) speciﬁcity for infection, (2) lack of bone marrow uptake,
which is a signiﬁcant advantage in imaging bone and joint
and orthopedic prostheses infections, (3) ease and cost of
preparation of the agent, (4) ex vivo labeling, which avoids
contact with blood and hence the risk of acquiring blood-
borne infections such as H1V and hepatitis B and C, (5) in-
dependence of the host inﬂammatory response and neu-
trophil count and hence it can be used to image infections in
immunocompromised patients, including those who are
neutropaenic, where culture is often negative and white cell
imaging unreliable, and (6) availability in a kit format with
long shelf-life, making it user friendly and more widely avail-
able[3].Certainstudieshaverevealedfalsepositive uptakeof
99mTc-ciproﬂoxacin in sterile inﬂammation questioning its
speciﬁcity [14–19].
3.10.2. 99mTc Sparﬂoxacin. Sparﬂoxacin is ﬂuoroquinolon,
antibiotic eﬀective against a wide range of Gram-positive ba-
cteria.Itwassuccessfullylabeledandevaluatedin invitroani-
mal model in which 99mTc-labeled antibiotic accumulated in
infective sites of live Staphylococcus aureus bacteria and re-
vealed no uptake in control models with heat-killed bacteria
[119].
3.10.3. 99mTc-Enroﬂaxacin. This is also quinolone antibiotic
used mainly in veterinary practice. Labeled with 99mTc,
in vitro studies did not show encouraging results in diﬀer-
entiating infection from inﬂammatory foci [120].
3.10.4. 99mTc-Ceftizoxime. Ceftizoxime is a 3rd-generation
cephalosporin eﬀective against a wide range of Gram-posi-
tive bacteria especially Staphylococcus aureus, Streptococci,
and Enterobacteriaceae. This drug is widely used at surgical
and medical ﬂoors as prophylactic and treatment antibiotic.
As per hypothesis, if such drugs are eﬀectively labeled with
radiotracerwithoutalteringtheeﬃcacyandeﬀectivebinding
with bacteria, localization of infective foci and monitoring
the eﬃcacy and duration of antibiotic treatment would be
a big hallmark. This drug was eﬀectively labeled with 99mTc
and used to localize bone infections as the penetration of this
antibiotic in bone is far better as compared with other an-
tibiotics [121].
3.10.5. 99mTc-Ethambutol. Ethambutolisanarrow-spectrum
antibiotic, which is active against mycobacteria (inhibits cell
wall mycolic acid synthesis) and is used as a ﬁrst-line drug
for the treatment of tuberculosis (TB). Hence radiolabeled
ethambutol is an attractive candidate for speciﬁcally imaging
mycobacterial infections, including early TB. Good results
wereobtainedinathighmodelofMycobacteriumtuberculosis
infection in mice and rabbits. 99mTc-ethambutol accumu-
lated at the site of infection as early as 2 hours after injection,
which increased at 4 hours and persisted till 24 hours. Fur-
ther studies with this agent are eagerly awaited [122].
3.10.6. 99mTc-INH. Isoniazid (INH) is a speciﬁc antituber-
culous drug showing selective uptake in live mycobacteria
basedonitsspeciﬁcinteractionwithmycolicacidwhichisan
important constituent of bacterial cell wall. This drug was
successfully labeled with 99mTc followed by studies on mice
and rabbits for labeling eﬃciency, in vitro and in vivo
stability,bloodkinetics,andorgandistribution.Thighmodel
of localized tubercular lesion was prepared in rabbits after
injecting 500μLo f3× 108 cells/mL of Mycobacterium tuber-
culosislivebacteriaingrowingphase(clinicalhumanisolate).
The localization of radiolabeled complex was studied with
70–75MBq of 99mTc-INH intravenously with successful
imaging at 2, 4, and 24 hours after tracer injection with
increase in target to nontarget (T/NT) ratio gradually up to
24hours.Labelingeﬃciencyofthekitwas>95%andonly2–
3.5%oftracerleakedoutfromthecomplexor24hourswhen
incubated in serum as 37◦C, conﬁrming its stability. Organ
distribution studies showed renal source of excretion with
no gastric or thyroid uptake suggesting good in vitro labeling
eﬃciency and stability. As controls, infection was induced in
rabbits with live Staphylococcus aureus after injection of 107
live bacteria followed by injection of same dose of 99mTc-
INH and imaging under same parameters. Tracer accumu-
lation was visualized in the infective foci from 2 hours
after injection; however, delayed imaging revealed gradual
clearance at 4 and 24 hours, which was in contradiction to
ﬁndings with tuberculous lesions. Overall more than 95%
sensitivity and high speciﬁcity were observed in the animal
study.Thereforeitwasconcludedthatthisradiolabeledagent
canbeusedfordetectionandfollowupoftuberculouslesions
in patients especially to determine the treatment endpoint
of antituberculous drugs [123]. Similar labeling of INH with
99mTc and study in humans was tried in our set up but we
were unable to localize lesions of tuberculous lymphadenitis
in humans with this radiotracer.
3.10.7. 99mTc-Fluconazole. Anticancer therapy, transplanta-
tion and AIDS give rise to infections with fungi such as Can-
dida albicans and Aspergillus Fumigatus. Fluconazole is anti-
fungal drug which was successfully labeled with 99mTc.
This labeled compound successfully detected infections with
Candida albicans but not bacterial infections or sterile in-
ﬂammatory sites in animals. There was good correlation be-
tween 99mTc-Fluconazole accumulation and the number of
viableCandidaalbicanswhichcouldbeusedasparameterfor
monitoring antifungal therapy. This agent is mainly excreted
viathekidneyswithlittleaccumulationintheliver.However,
it is not suited to detect Aspergillus fumigatus infections.
However, this radiotracer is able to distinguish between Can-
dida albicans infections from bacterial infections and sterile
inﬂammations [124].8 International Journal of Peptides
3.11. Detection of Infection by Antimicrobial Peptides. Pep-
tides are composed of relatively small components, the ami-
no acids. A diﬀerence between peptides and proteins is their
size. Peptides are compounds with up to about 50 amino
acids and a molecular mass below about 10,000 Dalton. In
contrast, they generally do not possess a well-deﬁned three-
dimensional (tertiary) structure. Because of the lack of
tertiary structure, small peptides are less susceptible to a
loss of integrity through labeling conditions and are less im-
munogenicthanproteins[125,126].Antimicrobialpeptides,
produced by phagocytes, epithelial cells, endothelial cells,
and many other cell types, are an important component of
innate immunity against infection by a variety of pathogens.
They can be expressed constitutively or induced during in-
ﬂammation or microbial challenge. These peptides, which
now number more than 100, with proven microbicidal ac-
tivity against a variety of microorganisms, share certain pro-
perties such as their small size and cationic charge. The
later allows them to bind preferentially to a broad spectrum
of microorganisms. Interestingly, the antibacterial eﬀect of
antimicrobial peptides in experimentally infected animals
might also be attributed to synergistic eﬀects with endoge-
nous antimicrobial peptides and proteins such as lysozyme
andsecretary leukoprotease inhibitor (SLPI),reactive oxygen
intermediates, or other local factors (such as pH, Ca+2 and
Zn+2 concentrations) or to interactions with host cells, lead-
ingtoenhancedantibacterialactivitiesofthecells[127–129].
4.Key Featuresof AntimicrobialPeptides
(i) Antimicrobial peptides usually contain <50 amino
acidswithanetpositivechargecreatedbyanexcessof
basic residues, such as lysine and arginine, and ∼50%
hydrophobic amino acids.
(ii) Antimicrobial peptides are essential components of
the innate host defense because of their ability to kill
a wide range of pathogens.
(iii) They have a wide distribution throughout the animal
and plant kingdoms.
(iv) They are eﬀectors of local and systemic immune re-
sponses. The latter is essentially found in insects.
(v) Although they share basic features such as small size,
hydrophobicity, and cationic character, antimicrobial
peptides have a great structural diversity.
(vi) The majority of antimicrobial peptides are derived
from larger precursors that harbor a signal sequence,
whereas other peptides are generated by proteolysis
from larger proteins (such as lactoferrin).
(vii) In addition, some antimicrobial peptides such as
mammalian defensins have other activities contrib-
uting to host defenses by mediating an acute inﬂam-
matory reaction and linking the innate with the ac-
quired immune response [130].
4.1. Preparation of Radiolabeled Peptides. Diﬃculties arising
in purifying natural antimicrobial peptides from various
sources have prompted the recombinant production of
Table 2: Natural and synthetic human antimicrobial peptides.
Peptide Amino
acids Amino acid sequence Code
Ubiquicidin
1–59 [20] UBI 1–59
1–18 KVHGSLARAGKVRGQTPK UBI 1–18
29–41 TGRAKRRMQYNRR UBI 29–41
18–29 KVAKQEKKKKKT UBI 18–29
18–35 KVAKQEKKKKKTGRAKRR UBI 18–35
31–38 RAKRRMQY UBI 31–38
22–35 QEKKKKKTGRAKRR UBI 22–35
Lactoferrin
1–692 [27] hLF
1–11 GRRRRSVQWCA hLF 1–11
2–11 RRRRSVQWCA hLF 2–11
3–11 RRRSVQWCA hLF 3–11
4–11 RRSVQWCA hLF 4–11
5–11 RSVQWCA hLF 5–11
6–11 SVQWCA hLF 6–11
21–31 FQWQRNMRKVR hLF 21–30
Defensin 1–3 1–30 [28]—
antimicrobial peptides by genetically engineered bacteria
or by peptide synthesis. Such methods result in suﬃcient
amounts of antimicrobial peptides produced under good
laboratory practice conditions, which is essential for use in
animal and human studies. Synthetic peptides are usually
small, rapidly removed from the circulation and other body
compartments, and ﬂexible, because they do not hold a pa-
rticular structure in a hydrophilic environment, and display
af a v o r a b l ea d v e r s ee ﬀect proﬁle.
4.2. Radiolabeling of Peptides. The aim of radiolabeling tech-
niquesistoﬁrmlyattachorincorporatetheradionuclideinto
the peptide without altering its biological functions, thus
allowing a reliable evaluation of its pharmacokinetics after
intravenousadministration.Thevariousmethodsoflabeling
peptides with 99mTc including indirect labeling using the
preformed chelate approach or bifunctional chelating agents
and the direct labeling method have been discussed exten-
sively [131]. The direct labeling method is a simple proce-
dure in which the peptide is labeled in absence of an exo-
genous chelator. The labeling of antimicrobial peptides is ra-
pid (within 10min), eﬀective (impurities, 5% of the total
radioactivity), stable (minimal release of radioactivity from
the 99mTc-peptide in diluted human serum), and safe (no
adverse eﬀects in mice and rabbits). Unfortunately, the re-
actionmechanismunderlyingthis 99mTc-labelingofpeptides
has not been elucidated. It may, however, involve the reduc-
tion of 99mTc, the production of a 99mTc intermediate, and
the substitution reaction transferring the reduced 99mTc
from this intermediate to the peptide [132].
4.3. Selection of 99mTc-Labeled Antimicrobial Peptides for
Scintigraphic Studies. In vitro binding studies were used to
select peptides displaying a preferential binding to microor-
ganisms over human cells from a range of 99mTc-labeledInternational Journal of Peptides 9
Antimicrobial peptide
Inner leaﬂet
Outer leaﬂet
Prototype plasma membrane of a
multicellular animal (erythrocyte)
Bacterial cytoplasmic membrane
Cholesterol Zwitterionic phospholipids
Acidic phospholipids
Trends in biotechnology
Weak Strong
+
t
plasma membrane of a
ar animal (erythrocyte)
Bacterial cytoplasmic membra
Weak Strong
+
Hydrophobic interactions Electrostatic and
hydrophobic interactions
+
−
− − −− − −
− − − −
+ + + +
Figure 1: The membrane target of antimicrobial peptides and the basis of their speciﬁc binding.
human antimicrobial peptides/proteins and synthetic pep-
tides derived from these natural peptides/proteins (Table 2).
Thereafter, a peritoneal infection model was used to assess
the in vivo binding of 99mTc-peptides to bacteria and host
cells. Next, radiolabeled peptides that had been selected by
this assay were injected into animals to ﬁnd out whether they
canbeusedtodiscriminateinfectionsfromsterileinﬂamma-
tory lesions using scintigraphic techniques. Peptides were
also selected on the basis of favorable pharmacokinetics. Aft-
er these phases of selection, α-defensins and several peptides
derived from ubiquicidin were seen to be the most likely
candidates for infection detection [133].
4.4. Mechanism of Labeled Peptides for Infection Detection.
Although antimicrobial peptides have diﬀerent chemical
structures, the basis of their antimicrobial activities is the in-
teraction of the cationic (positively charged) domains of the
peptides with the (negatively charged) surface of microor-
ganisms (Figure 1). Given that microbial membranes expose
negatively charged phospholipids, such as LPS or teichoic
acids, on their surface, whereas mammalian cells segregate
lipids with negatively charged head groups into the inner
leaﬂet, it is conceivable that antimicrobial peptides bind pre-
ferentially to pathogens over mammalian cells [130].
4.5. Antimicrobial Peptides in Experimental Use. One of the
best-studied antimicrobial peptides is human neutrophil pe-
ptide-1 (HNP-1), which is a member of the family defen-
sins. Initially, the potential use of HNP-1 for antibacterial
therapy of experimental infections in mice was studied. The
antibacterial eﬀect was found to be associated with an in-
creasedinﬂuxofneutrophilsintotheinfectedarea[134].Use
of this agent in experimental thigh muscle infection in mice
allowedrapidvisualizationofbacterialinfections,butabscess
to background ratios were low and decreased with time
[135, 136].
4.6. Imaging of Infections in Immunocompromised Mice. Im-
munocompromised mice produced by an injection of cy-
clophosphamide were utilized for detection of infection site
induced by microorganisms which conﬁrmed that accumu-
lation of tracer was due to microorganisms, not due to in-
ﬂammatory cells [24]. In immunocompromised animals the
accumulation of the peptide at the infection site was similar
to that in immunocompetent rabbits, thus conﬁrming in-
signiﬁcant contribution of the labeling with activated leuko-
cytes and other inﬂammatory cells [27, 28].
4.7. Discrimination between Infection and Inﬂammation. An-
timicrobial peptides labeled with 99mTc selectively localized
theinfectionsitesofbacteriaandfungithroughbinding with
their cell membranes and revealed minimum or no uptake in
inﬂammatory model induced by LPS or heat-killed micro-
organisms [24]. Similarly, no binding of labeled 99mTc-an-
timicrobial peptide UBI (29–41) was appreciated in inﬂam-
matory models in rabbits induced with formalin-killed Sta-
phylococcus aureus bacteria or turpentine oil [27].
4.8. Ubiquicidin (UBI 29–41): New Antimicrobial Peptide.
UBI(29–41)(TGRAKRRMQYNRR,1,693Da)wasoriginally10 International Journal of Peptides
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Figure 2: Structure of UBI 29–41.
isolated from the cytosolic fraction of IFN-γ-activated cells
of mouse macrophage cell line RAW264.7 (Figure 2). Later,
an identical UBI was isolated from human H292 airway
epithelial cells. Ubiquicidin is identical or highly homolo-
gous to S30, a protein that was puriﬁed from the small ribo-
somal subunit fraction of rat liver and shown to be present
in various human and murine tissues. The homology of
the precursor element of this protein to ubiquitin and the
fact that it is probably widely expressed named this protein
ubiquicidin (Latin “ubique,” everywhere) [137].
4.8.1. Radiochemical Analysis. HPLC chromatograms for
UBI peptides indicated that the preparations were more
than 95% pure. ITLC analysis of the preparation containing
radiolabeled peptide showed peptide-labeling yield of 98%
after 10 minutes of incubation and these values remained
u n c h a n g e du pt o2 4h o u r s[ 20].
4.8.2. Stability of 99mTc-Labeled UBI in Human Serum. Sta-
bility of the 99mTc-labeled UBI peptides was assessed by in-
cubating one volume of the labeling solution with one vol-
ume of 20% (v/v) human serum in saline for 1 and 24
hours at 37◦C. Next, the amounts of free pertechnetate and
99mTc-peptide in the samples were determined by ITLC
using methyl ethyl ketone as eluent. Results showed minimal
release of radioactivity from the 99mTc-UBI peptides. ITLC
analysis of the samples after 1 and 24 hours of incubation in
human serum revealed small amounts of released/free 99mTc
(<3% of the total activity at both intervals) [138].
4.8.3. Binding of UBI to Bacteria and Murine Blood Cells.
Analysis of murine blood revealed that only a small propor-
tion of the intravenously injected 99mTC-UBI is associated
with blood cells. Moreover, injection of excess unlabeled
UBI 29–41 into Staphylococcus-aureus-infected mice prior
to injection of 99mTc UBI 29–41 signiﬁcantly (P<0.05)
reduced the accumulation of this radiopharmaceutical at the
site of infection. In addition, signiﬁcantly (P<0.01) higher
amounts of 99mTc-UBI 29–41 accumulated at the site of
infection in mice using a carrier-free radiolabeled UBI 29–41
as compared with unpuriﬁed preparation containing radio-
labeled UBI 29–41 [20].
4.8.4.InVitroBindingofUBIandTwoOtherCationicPeptides
to Bacteria and Tumor Cell Lines. A comparative study of the
in vitro binding of 99mTc-UBI and two diﬀerent 99mTc-label-
ed cationic peptides (99mTc-Tat-1-Scr and 99mTc-Tat-2-Scr)
to bacteria and to two tumor cell lines (LS174T and ACHN)
was performed. The binding of 99mTc-UBI, 99mTc-Tat-1-Scr,
and 99mTc-Tat-2-Scr to Staphylococcus aureus was 35%, 78%,
and 87%, respectively. While the binding of 99mTc-Tat-1-Scr
and 99mTc-Tat-2-Scr was 37% and 33% to colon tumor cells
(LS174T) and 39% and 41% to renal tumor cells (ACHN),
respectively. Binding of 99mTc-UBI to both cell types was
much lower (<4%) [138].
4.8.5. In Vivo Binding Studies. Experimental peritoneal in-
fectioninmiceshowedhighestbindingof 99mTc-labeledUBI
peptides to bacteria. The mean ratio between binding of UBI
peptides to bacteria and that to leukocytes, determined at 2
and 24 hours, amounted to 73–220 [20]. The in vivo speci-
ﬁcity of 99mTc-UBI for infection in mice was also evaluated
using dual labels in the same animal and comparing the
target/nontarget ratio for 67Ga-citrate and 99mTc-UBI at sites
of induced infection and sterile inﬂammation. This study
revealed that there is a signiﬁcant diﬀerence (P<0.05) in the
radioactive accumulation of 99mTc-UBI between the sites of
infection and inﬂammation compared to 67Ga-citrate. Thus,
99mTc-UBI showed an average infection/inﬂammation ratio
of 2.08 ± 0.49 compared to 1.14 ± 0.45 for 67Ga-citrate. In
conclusion, the in vitro and in vivo results provide evidence
that a speciﬁc mechanism is responsible for the 99mTc-UBI
bacterial intracellular accumulation [138].
4.8.6. Infection Imaging in Animal Models. In experimental
animals, various 99mTc-labeled UBI peptides visualized the
bacterial or fungal infected tissues within 30 minutes after
injection. A good correlation between the accumulations of
99mTc-labeled UBI peptides in Staphylococcus-aureus-infec-
ted thigh muscles in mice and the number of viable bac-
teria present at the site of infection was recorded. In immu-
nocompromised animals the accumulation of the peptide at
the site of infection seemed to be similar to that in immuno-
competent mice, conﬁrming the insigniﬁcant contributionInternational Journal of Peptides 11
Figure 3: Biodistribution of 99mTc UBI 29–41 in a normal rabbit at 30 minutes after injection.
5 min 15 min
30 min 60 min
Figure 4: 99mTc-UBI(29–41)scintigramofrabbitwithStaphylococ-
cus aureus thigh muscle infection (arrow). Maximum tracer uptake
visualized at 60 minutes after tracer injection.
of the direct binding of the tracer to inﬁltrating leucocytes
[133].
4.8.7. Discrimination between Bacterial Infection and Sterile
Inﬂammation. Variousexperimentalthighmuscleinfections
in mice and rabbits with both Gram-positive and Gram-neg-
ative bacteria revealed accumulation of 99mTc-labeled UBI at
the site of infection within 15–30 minutes after injection. No
signiﬁcant accumulation of labeled peptide was observed in
thighs of rabbits and mice previously injected with LPS or
heat-killed bacteria (i.e., sterile inﬂammation) [133]. Only
one animal model study provided results against its binding
to bacteria and concluded its aﬃnity for 3H-deoxyglucose
and macrophage accumulation at the site of infection [139].
4.8.8. Biodistribution of UBI in Mice and Rabbits. After in-
jection, 99mTc-labeled UBI peptides are rapidly removed
from the circulation via the kidneys. Scintigraphic analysis
revealed that, within the ﬁrst hour after injection of tracer,
major part of activity was found in kidneys and urinary
bladder with little accumulation in liver, lungs, and spleen
(Figure 3)[ 20, 27, 133].
4.8.9. Infection Detection with 99mTc UBI 29–41 in Animal
Model. 99mTc UBI was evaluated as bacterial infection seek-
ing agent in Staphylococcus aureus and Escherichia coli infec-
tions in rabbit model. It was concluded that the agent can
detect both bacterial infections from sterile inﬂammatory
sites and showed more tracer accumulation in Staphylococcus
aureus infections compared with Escherichia coli infections.
Optimum time for imaging was 60 minutes after tracer in-
jection (Figure 4)[ 20]. This peptide also permitted early
speciﬁc detection of experimental Staphylococcus aureus pro-
sthetic joint infections in animal model and resulted in early
detection of acute prosthetic joint infection and diﬀerenti-
ated well from chronic sterile prosthetic joint inﬂammation
[140]. Endocarditis is another diﬃcult diagnostic question
from cardiologist. In an animal study radiolabeled UBI12 International Journal of Peptides
Figure 5:Anteriorwholebodyimageat30minutesafter 99mTc-UBI
29–41 injection in normal human subject showing kidneys (dotted
arrows), liver (solid arrows), and urinary bladder (ball arrow).
29–41 scintigraphy revealed early and speciﬁc detection
of multidrug-resistant Staphylococcus-aureus-induced endo-
carditis. Furthermore it was concluded that accumulation
of tracer depends on the number of viable bacteria in the
vegetation and declared it as dedicated noninvasive imaging
tool for early detection of infective endocarditis [141].
4.8.10. 99mT cU B IS c a nf o rD e t e c t i o no fF u n g a lI n f e c t i o n si n
Animals. 99mTc UBI imaging was also studied in animal
models for localization of infection induced with Candida
albicans. It was observed that this antimicrobial peptide
showed signiﬁcant accumulation at the site of infection com-
pared with sterile inﬂammation [142]. This peptide showed
binding with Candida albicans and Aspergillus fumigatus in
addition to viable bacteria. Therefore this agent is useful
for detection of fungal infections; however diﬀerentiation
would be diﬃcult from bacterial infections. However 99mTc-
ﬂuconazole can be used later on, which binds only with Ca-
ndidaalbicans,showsnobinding tobacteriaandnoaccumu-
lation at site of sterile inﬂammation [143].
4.8.11. 99mTc UBI for Monitoring Eﬃcacy of Antibacterial
Agents. 99mTc-UBI when injected into Staphylococcus-au-
reus-infected mice after treatment with various doses of
cloxacillin and erythromycin showed inverse correlation
between accumulation of the peptide at the site of infection
and the dose of antibacterial agents. Good correlation was
observed between the accumulation of 99mTc-UBI and the
number of viable bacteria. These results indicated the poten-
tial of the peptide for evaluating the eﬃcacy of antibiotic
therapy. However, minimum number of bacteria that can be
detected was 103–104, which is the limitation for monitoring
the eﬀects of the antibacterial agents [144]. Same conclusion
was drawn in another study in which commonly used broad-
spectrum antibiotic ciproﬂoxacin was used in a rabbit mod-
el. It also revealed that the radiotracer can be used for moni-
toring eﬃcacy and duration of antibiotic treatment [28].
4.8.12. Biodistribution in Humans. 99mTc-UBI was investiga-
ted in a biokinetic model to evaluate its feasibility as an
infectionimagingagentinhumans.Wholebodyimagesfrom
6 children with suspected bone infection were acquired at 1,
30, 120, 240 minutes and 24 hours after tracer administra-
tion. Regions of interest (ROIs) were drawn around source
organs (heart, liver, kidneys, and bladder) on each time
frame. The same set of ROIs was used for all 6 scans and the
counts per minutes (cpm) of each ROI were converted to
activity using the conjugate view counting method. Counts
were corrected by physical decay and by the background cor-
rection factor derived from preclinical phantom studies. The
image sequence was used to extrapolate 99mTc-UBI time-ac-
tivity curves in each organ and calculate the cumulated
activity. Urine samples were used to obtain the cumulative
percentofinjectedactivityversustimerenalelimination.The
absorbed dose in organs was evaluated according to the gen-
eral equation described in the MIRD formula. In addition,
67Ga-citrate images were obtained from all the patients and
used as a control. Biokinetic data showed a fast blood clear-
ancewithameanresidencetimeof0.52hour.Approximately
85%oftheinjectedactivitywaseliminatedbyrenalclearance
24 hours after 99mTc-UBI administration. Images showed
minimal accumulation in nontarget tissues with an average
target/nontarget ratio of 2.18 ± 0.74 in positive lesions at 2
hours. All infection positive images were in agreement with
those obtained with 67Ga-citrate. The mean radiation-ab-
sorbed dose calculated was 0.13mGy/MBq for kidneys and
the eﬀective dose was 4.34 × 10
−3 mSv/MBq [145]. Biodis-
tribution of thepeptide wasalsostudied in 3 normalsubjects
inanotherstudybytakinganteriorandposteriorwholebody
images and using geometric mean method. It was observed
thatthetracermainlyexcretedthroughthekidneysintourin-
ary bladder followed by liver with no other site of accumula-
tion in the body (Figure 5)[ 27].
4.8.13. Bacterial Infection Detection in Humans with 99mTc
UBI 29–41. 99mTc UBI 29–41 showed good correlation for
infection detection in humans when compared with 67Ga
imaging of the same subjects [145]. In another study the
agent was tested in patients suﬀering from bone, soft tis-
sue,orprosthesisinfectionsandencouragingresultswereob-
served with overall sensitivity, speciﬁcity, and accuracy of
100%, 80%, and 94.4%, respectively. Maximum tracer
accumulation was noted at 30 minutes after tracer injection
(Figure 6)[ 29].International Journal of Peptides 13
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Figure 6: Positive 99mTc-UBI 29–41 scan in a patient with infection in medial aspect of right hand (arrow). Maximum focal increased tracer
uptake was seen at 30 minutes after tracer injection.
This peptide yielded fast and promising results in pa-
tients with suspected mediastinitis after cardiac surgery.
Qualitative analysis correctly identiﬁed infection in 5/6 pa-
tients with proven mediastinitis on bacterial culture [146].
Fever of unknown origin (FUO) is also a diagnostic dilemma
for physicians and surgeons. Antibiotics are blindly used
without localizing the infective focus. This antimicrobial pe-
ptide revealed speciﬁcity of 95.35% for localizing infection
and discarding sterile inﬂammation. Sensitivity was 97.52%
with high accuracy [147]. Vertebral osteomyelitis is diﬃcult
to diagnose by noninvasive diagnostic modalities including
CT, MRI, radionuclide bone scan, and X-Ray. Even 67Ga scan
is nonspeciﬁc test which is considered better than other diag-
nostic techniques. As UBI 29–41 has special aﬃnity for bind-
ing to viable bacteria, this has been used for conﬁrmation of
vertebral infection which showed 100% sensitivity and 88%
speciﬁcity [148]. Noninvasive diagnostic techniques includ-
ing three-phase bone scan, MRI, and 99mTc-UBI 29–41 scan
for detection of osteomyelitis were compared. Antimicrobial
peptide showed 100% accuracy with maximum mean target
to nontarget ratio at 15 minutes after tracer injection, while
three-phasebonescanandMRIrevealed90%and75%accu-
racy, respectively. This study revealed superiority of antimi-
crobial peptide imaging over bone scan and MRI [149].
4.8.14. 99mTc-UBI Scan for Monitoring Eﬃcacy of Antibiotic
Treatment in Human Infections. As mentioned in animal
studies, binding of 99mTc UBI 29–41 to viable bacteria is pro-
portional to their number in the infective focus. Intensity of
tracer uptake decreased when number of viable bacteria was
reduced. Therefore it was concluded that this tracer can be
used for monitoring eﬃcacy and duration of treatment
[28, 144]. Similar study for monitoring antibiotic therapy
in patients with orthopaedic infections showed better results
on quantitative analysis of scan at 30, 60, and 120 minutes
after tracer injection after 10–14, day interval with antibiotic
treatment when compared with erythrocyte sedimentation
rate, C-reactive protein, and radioisotope bone scan [150].
5.Limitationsof AntimicrobialPeptides
5.1. Lack of Discrimination between Diﬀerent Infectious
Agents. 99mTc-labeled antimicrobial peptides bind to fungi
in addition to bacterial cell membranes; however, infection
e i t h e rf r o mb a c t e r i ao rf u n g ic a nb ed i ﬀerentiated from ster-
ile inﬂammatory sites [24]. Similarly, there is nonuniform
accumulation of radiolabeled peptides in diﬀerent types of
bacteria. Staphylococcus aureus showed more uptake than
Escherichia coli which may be due to diﬀerent mode of toxi-
city [27].
5.2.LackofDetectionofIntracellularPathogens. Radiolabeled
peptides bind to the cell membranes of the bacteria. How-
ever, if the bacteria are engulfed by the anti-inﬂammatory
cells or become intracellular after invasion of the host im-
mune cells, their detection would become diﬃcult with scin-
tigraphy [123].
5.3. Resistance against Antimicrobial Peptides. Major concern
with use of the labeled antibiotics as speciﬁc infection locali-
zation tracers is the development of resistance. Similar
situation may also be encountered with antimicrobial pep-
tides. Some Gram-negative bacteria can modify the lipid-A
moiety of the endotoxin [151]. Similarly Gram-positive
b a c t e r i ac a nr e d u c en e g a t i v ec h a r g eo ft h eb a c t e r i a ls u r f a c e14 International Journal of Peptides
by esteriﬁcation of phospholipids of Staphylococcus aureus
[152]. Inactivation of antimicrobial peptides by bacterial
serine proteases can prevent intracellular accumulation of
the peptides [153]. However, in multiple studies conducted
with diﬀerent radiolabeled antimicrobial peptides including
UBI (29–41) have not revealed such evidence up till now.
6. Conclusion
The medical community often faces the dilemma of discrim-
ination between infection and inﬂammation on medical as
well as on surgical ﬂoors. Nonspeciﬁc radiotracers for loca-
lization of infection/inﬂammation do not solve the problem.
Among the speciﬁc radiotracers for localization of infection,
antibiotics gained more popularity due to easy availability,
labeling, low cost, and high sensitivity. Among the labeled
antibiotics ciproﬂoxacin was the most successful speciﬁc ba-
cterial localization agent which showed sensitivity of 85.4%
and speciﬁcity of 81.7% [117]. However, emerging antibi-
otic resistance against antibiotics is also associated with
ciproﬂoxacin [154]. False uptake of 99mTc-ciproﬂoxacin in
sterile inﬂammation is also a big disadvantage [14]. Due to
nonspeciﬁc accumulation in inﬂammatory sites, this agent
has been proposed for identifying the presence and distribu-
tion of inﬂammation in joints [18].
On the other hand, antimicrobial peptides labeled with
isotopes are better speciﬁc infection localizing agents as they
bind speciﬁcally to bacterial cell membranes. These tracers
detect Gram-positive, Gram-negative bacteria, Candida albi-
cans and Aspergillus Fumigatus infections. The amount of
radiolabeled peptides at the site of infection depends on the
number of viable organisms present at the focus. Recently
investigated antimicrobial peptide, ubiquicidin UBI (29–41)
has shown encouraging results in human clinical trials. This
peptide can also be used for monitoring eﬃcacy and dura-
tion of antibiotic treatment in patients which is very im-
portant issue from prophylactic, therapeutic, and socioeco-
nomic point of view. No doubt, there are limitations at-
tributed to synthesis/isolation of such peptides, labeling with
isotopes, minimum detection limit of 103 Colony-Forming
Unit (CFU) of bacteria, and inability to distinguish between
bacterial and fungal infections. In addition, diﬀerent bac-
terial types reveal diﬀerent tracer accumulation (Staphylo-
coccus aureus versus Escherichia coli). Currently no evidence
regarding resistance against antimicrobial peptides has been
reported. Considering the merits and demerits of radiola-
beled peptides and radiolabeled antibiotics, it can currently
be concluded that radiolabeled peptides are better speciﬁc
infection localizing agents.
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